Astrazeneca AZN Institutional Ownership

Ownership Summary

Astrazeneca Plc (NYSE:AZN) has 1,286 institutional investors that have filed 13F reports for the period ending March 2026.

• They owned 48.9% of outstanding stock in March 2026, up from 0.0% the prior quarter.
• They increased total shares held in Astrazeneca by 170379.7% from last quarter, and the number of investors in AZN increased 64200.0% annually.
• Among the 1,286 funds, 1,263 bought more Astrazeneca shares, 19 sold down, and 4 held their ground.
• The aggregate institutional position in Astrazeneca amounted to 757.71Mn shares as of March 2026, up by 757.27Mn shares quarter on quarter, and up 757.62Mn shares year over year.
• INVESTOR AB leads ownership in AZN with 51.59Mn shares as of March 31, 2026, equal to 3.33% of outstanding shares.
• Top purchasers of AZN stock for the quarter ending March 2026 included INVESTOR AB (51.59Mn), VANGUARD CAPITAL MANAGEMENT LLC (45.04Mn), Capital International Investors (34.39Mn), FMR LLC (29.6Mn), Capital World Investors (28.26Mn).
• Leading sellers of Astrazeneca shares for the quarter ending March 2026 were L & S Advisors Inc (18.73K), Icon Wealth Advisors, LLC (1.8K), EverSource Wealth Advisors, LLC (1.57K), Valeo Financial Advisors, LLC (1.17K), Boston Common Asset Management, LLC (752).
• Business Quant data shows the 10 biggest positions in Astrazeneca as of March 2026 are held by INVESTOR AB (51.59Mn), VANGUARD CAPITAL MANAGEMENT LLC (45.04Mn), Capital International Investors (34.39Mn), FMR LLC (29.6Mn), Capital World Investors (28.26Mn), Legal & General Group Plc (25.85Mn), Janus Henderson Group Plc (23.9Mn), WELLINGTON MANAGEMENT GROUP LLP (23.75Mn), PRICE T ROWE ASSOCIATES INC /MD/ (19.49Mn), Bank Of America Corp /De/ (19.06Mn).